Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 16 of 16 for “"Naglu"”.
-
Purification of human recombinant Naglu from Sf9 cells and uptake studies with MPS IIIB fibroblasts
… lysosomal hydrolase, α-N-acetylglucosaminidase (Naglu). Naglu is a housekeeping enzyme involved in the degradation pathway of heparan sulfate. A deficiency in active Naglu leads to an accumulation of heparan sulfate within the lysosome, initiating a pathological cascade within the cell. Patients …
-
Expression of alpha-N-acetylglucosaminidase fused to the HIV-1 protein transduction domain and a modified protein transduction domain
… in the enzyme alpha-Nacetylglucosarninidase (Naglu). Recombinant Naglu is unable to enter cells or cross the blood-brain barrier (BBB), making potential enzyme replacement therapy infeasible. To enable Naglu to be endocytosed by cells and perhaps cross the BBB, two fusion proteins of Naglu …
-
The expression of alpha-N-acetylglucosaminidase in two heterologous gene expression systems
… by a defect in alpha-N-acetylglucosaminidase (NAGLU), a lysosomal enzyme involved in the degradation of heparan sulphate. Dysfunctional NAGLU gives rise to a clinical phenotype of severe and progressive mental retardation, often accompanied by hyperactivity and aggressive behaviour. At present, …
-
Purification and Uptake Studies of Recombinant Human N-α-D-Acetylglucosaminidase from Sf9 Insect Cells
Human α-N-acetylglucosaminidase (Naglu) is a lysosomal enzyme implicated in the rare metabolic storage disorder Mucopolysaccharidosis III type B (MPS IIIB). A deficiency in Naglu results in a buildup of heparan sulfate in lysosomes, which is most detrimental in the central nervous system, causing …
-
Expression of human α-N-Acetylglucosaminidase in Sf9 insect cells: effect of cryptic splice site removal and native secretion-signaling peptide addition.
Human α-N-Acetylglucosaminidase (Naglu) is a lysosomal acid hydrolase implicated in tthe rare metabolic storage disorder known as mucopolysaccharidosis type IIIB (MPS IIIB; also Sanfilippo syndrome B). Absence of this enzyme results in cytotoxic accumulation of heparan sulphate in the central …
-
The expression of α-N-acetylglucosaminidase in the methylotrophic yeast Pichia pastoris
… of the gene encoding a-N-acetylglucosaminidase (Naglu) results in the inability to degrade the GAG heparan sulfate (HS). Consequently. undegraded HS builds up and results in the secondary accumulation of gangliosides and substantial changes in the expression of genes related to neural cell growth …
-
Molecular techniques for therapeutic and diagnostic applications in Mucopolysaccharidosis IIIB and Gaucher disease
… IIIB (MPS IIIB). Mutations in NAGLU and GBA1, the genes that encode for lysosomal hydrolases required for degradation of heparan sulfate and glucocerebrosides, lead to the observed pathogenesis in MPS IIIB and GD, respectively. Since many LDs, including MPS IIIB and some forms …
-
Development of Newborn Screening Methods for Mucopolysaccharidosis III type A and type B in Dried Blood Spot using Tandem Mass Spectrometry
… by the deficiency of N-acetyl glucosaminidase (NAGLU) in the lysosome and the inability to degrade a polysaccharide called heparan sulfate. NAGLU is a downstream enzyme of sulfamidase, which causes MPS III A. Sulfamidase and NAGLU are working together with several other enzymes, acetyl-CoA: …
-
Structural and functional studies on secreted glycoside hydrolases produced by clostridium perfringens
… to the human α-N-acetylglucosaminidase, NAGLU, in which mutations can cause a devastating genetic disease called mucopolysaccharidosis IIIB. One striking feature of the secreted glycoside hydrolase enzymes of C. perfringens is their modularity, with modules predicted to be dedicated to …
-
Effects of oral Ambroxol on neuropathological measures in the canine model of Sanfilippo Syndrome type B
… of MPS. A lack of ?-N-acetyl glucosaminidase (NAGLU) activity causes MPS IIIB, which is characterized by the predominant accumulation of HS. Currently, MPS IIIB has no approved treatments. It is particularly desirable to use gene therapy to treat NAGLU deficiency in MPS IIIB patients, as any …
-
A Drosophila Model of Mucopolysacchridosis IIIA
… genes, including N-acetyl-alpha-glycosaminidase (Naglu) and N-acetylglucosamine 6-Sulfatase (GNS), which are both downstream from Sgsh in the HS catabolic pathway. Disruption of Sgsh expression impacts multiple interrelated biological processes, including developmental pathways, transcriptional …
-
Mucopolysaccharidosis type IIIB and GalNAc Transferase double knockout mice and additional studies in gene therapy and animal models to assess pathogenesis and therapy
… deficiency of N-acetyl-α-D-glucosaminidase (Naglu) activity which leads to lysosomal accumulation of HS as a primary storage substrate, and secondary accumulation GM2 and GM3 gangliosides. Mucopolysaccharidosis type IIIC is characterized by deficiency of the HSGNAT gene product, a lysosomal …
-
Mucopolissacaridose IIIB : avaliação clínica, bioquímica e epidemiológica de pacientes brasileiros
A deficiência da atividade enzimática da NAGLU e o subsequente acúmulo de Heparan sulfato nos tecidos corporais causam a Mucopolissacaridose IIIB, uma doença lisossomal caracterizada por manifestações principalmente neurológicas, mas em menor grau, em manifestações somáticas. Não há uma …
-
COMPUTATIONAL METHODS IN MISSENSE MUTATION ANALYSIS: PHENOTYPES, PATHOGENICITY, AND PROTEIN ENGINEERING
… the enzyme activity of missense mutations in NAGLU (N-Acetyl-Alpha-Glucosaminidase) and second in predicting the relative growth rate of mutated human SUMO-ligase in a yeast complementation assay. I also demonstrated the effectiveness of the new ensemble method for addressing a key problem …
-
Neuropathologic characterization of a canine model of mucopolysaccharidosis IIIB and additional studies in anti-inflammatory therapy and neuroinflammatory kinetics
… from a deficiency in ?-N-acetylglucosamindase (Naglu) activity which results in primary accumulation of HS. There is currently no approved treatment for MPS IIIB, however, enzyme replacement therapy, gene therapy, and anti-inflammatory therapies are currently being examined. A knock-out mouse …
-
Defining the neuropathological impact of heterozygosity in the gene encoding sulfamidase, a lysosomal degradative enzyme
… data suggests that carriers of GBA, NPC1, SMPD1, NAGLU, and SGSH mutations may be at increased risk of later-onset neurological conditions such as Parkinson’s disease. This is exemplified in carriers of mutations in the glucosylceramide beta- 1 and granulin genes, who are at increased risk of …